Breaking News Instant updates and real-time market news.

STJ

Acquired by ABT

$77.66

-0.32 (-0.41%)

, ABT

Abbott

$40.59

-0.2 (-0.49%)

08:01
10/18/16
10/18
08:01
10/18/16
08:01

St. Jude Medical, Abbott to sell part of vascular closure business to Terumo

STJ

Acquired by ABT

$77.66

-0.32 (-0.41%)

ABT

Abbott

$40.59

-0.2 (-0.49%)

  • 19

    Oct

  • 19

    Oct

  • 26

    Oct

  • 06

    Nov

STJ Acquired by ABT
$77.66

-0.32 (-0.41%)

08/29/16
FBCO
08/29/16
NO CHANGE
FBCO
St. Jude Medical can fix security deficiencies, says Credit Suisse
After speaking with "a developer of software used in drugs/devices" about Muddy Waters' security concerns regarding St. Jude's CRM system, Credit Suisse analyst Matthew Keeler says the consultant believes that the security deficiencies,can be fixed. According to the consultant, the deficiencies can be fixed using a five to ten person team working for about three months, Keeler stated. Keeler does not think that St. Jude's pending acquisition by Abbott (ABT) will be impacted by Muddy Waters' report. He keeps an $81 price target and Neutral rating on St. Jude.
09/08/16
PIPR
09/08/16
NO CHANGE
Target $82
PIPR
Neutral
Piper sees little reason to believe St. Jude deal will not close
Piper Jaffray analyst Brooks West says cybersecurity expert Mark Lanterman during a conference call yesterday refuted security claims by MedSec and Muddy Waters against St. Jude Medical's (STJ) pacemakers, defibrillators and Merlin monitoring system. Lanterman stated that there is "not much meat on the bone" to the MedSec claims and the quality of the analysis, West tells investors in a research note. He notes that Abbott (ABT) yesterday at a competitor conference earlier stated the St. Jude acquisition was progressing toward a close before year-end. The analyst sees little reason to believe the transaction will not close in the planned timeframe. West reiterates a Neutral rating on St. Jude.
09/19/16
JEFF
09/19/16
NO CHANGE
Target $48
JEFF
Buy
Abbott unit sale does not impact Alere transaction, says Jefferies
Jefferies analyst Jeffrey Holford believes Abbott's (ABT) sale of its Medical Optics business to Johnson & Johnson (JNJ) does not imply an increased probability that the Alere (ALR) deal will close. After speaking to Abbott management, Holford thinks the proceeds from the sale are more likely to be targeted towards the St. Jude Medical (STJ) acquisition. He believes that deal has a higher probability of closing than Alere. Holford has a Buy rating on Abbott with a $48 price target.
10/11/16
COWN
10/11/16
NO CHANGE
Target $85
COWN
Outperform
Cowen says St. Jude advisory common for the industry
While Dear Doctor letters are never a positive, St. Jude Medical's (STJ) medical device advisory relating to a low rate of premature battery depletion in the high voltage portfolio is common in the Cardiac Rhythm Management industry, Cowen analyst Joshua Jennings tells investors in a research note. The analyst sees limited risk to St. Jude's franchise and still expects the takeover by Abbott Laboratories' (ABT) to close by the end of the year. Jennings keeps an Outperform rating on St. Jude shares with an $85 price target. The stock is down 1% to $80.19 in pre-market trading.
ABT Abbott
$40.59

-0.2 (-0.49%)

09/29/16
COWN
09/29/16
NO CHANGE
COWN
Outperform
Cowen says views on Dexcom, Insulet not changed by competitor launches
Cowen analyst Doug Schenkel noted that Abbott (ABT) announced yesterday it had received FDA approval for the professional version of its FreeStyle Libre glucose monitoring product and filed the consumer version of Libre, while Medtronic (MDT) also announced FDA approval of its 670G Hybrid Closed Loop system. Schenkel said Abbott's consumer Libre filing comes a few months ahead of his expectations but that Medtronic's timing was in-line with expectations. The analyst said the competitor announcements, which had been expected, do not change his views on DexCom (DXCM), Insulet (PODD), or Tandem Diabetes (TNDM) and he keeps Outperform ratings on all three of those stocks.
09/29/16
ADAM
09/29/16
NO CHANGE
Target $53
ADAM
Buy
Alere risk-reward looks 'quite good' as deal debate nears end, says Canaccord
Canaccord analyst Mark Massaro said he is optimistic that a conclusion of Abbott (ABT) and Alere's (ALR) merger fight is "not far off" and he still believes Abbott will ultimately acquire Alere, though he also thinks the merger may be decided by a judge. Massaro puts a 65% probability on the likelihood the deal closes at the $56 deal price, a 30% chance that Abbott buys Alere at a lower price nearer to $50 per share, and only a 5% chance the deal breaks, making the risk-reward ratio in Alere shares at current levels "quite good," he tells investors. He trimmed his price target on Alere to $53 from $56 an keeps a Buy rating on the stock.
09/29/16
BARD
09/29/16
NO CHANGE
BARD
Dexcom, Insulet could be weighed down by competitive concerns, says Baird
Baird analyst Jeff Johnson said that while the FDA approvals announced yesterday for Abbott's (ABT) FreeStyle Libre Pro and Medtronic's (MDT) 670G were largely anticipated, he believes that both approvals came sooner than most expected, as did news that Abbott also recently filed for FDA approval of its consumer Libre system. The approvals could "change the narrative" in diabetes and could weigh on others in the sector in the near-term, most notably Dexcom (DXCM) and Insulet (PODD), Johnson tells investors. He keeps Neutral ratings on both and maintains an Overweight rating on Tandem Diabetes (TNDM), citing valuation for the difference.

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

15:17
11/22/17
11/22
15:17
11/22/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
11/22/17
11/22
15:16
11/22/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRX

Valeant

$16.68

0.685 (4.28%)

15:10
11/22/17
11/22
15:10
11/22/17
15:10
Options
$2M DOOM puts opened in Valeant tied to hedge »

$2M DOOM puts opened in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 18

    Jun

FTR

Frontier Communications

$7.08

-0.15 (-2.07%)

15:05
11/22/17
11/22
15:05
11/22/17
15:05
Options
Frontier Communications call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:00
11/22/17
11/22
15:00
11/22/17
15:00
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

14:55
11/22/17
11/22
14:55
11/22/17
14:55
General news
FX Action: The dollar faded further »

FX Action: The dollar…

MCD

McDonald's

$169.13

0.8301 (0.49%)

14:53
11/22/17
11/22
14:53
11/22/17
14:53
Periodicals
McDonald's temporarily pulling chicken tenders due to high demand, BI reports »

McDonald's, unable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLM

Sallie Mae

$10.60

-0.03 (-0.28%)

14:50
11/22/17
11/22
14:50
11/22/17
14:50
Options
SLM sees bullish option flow »

SLM sees bullish option…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SQM

SQM

$56.50

-0.835 (-1.46%)

14:49
11/22/17
11/22
14:49
11/22/17
14:49
Options
SQM options imply 5.9% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,139.49

13.18 (1.17%)

, WMT

Wal-Mart

$96.39

-0.13 (-0.13%)

14:42
11/22/17
11/22
14:42
11/22/17
14:42
Periodicals
Online shopping already set new record, CNBC reports »

With Black Friday and…

AMZN

Amazon.com

$1,139.49

13.18 (1.17%)

WMT

Wal-Mart

$96.39

-0.13 (-0.13%)

BBY

Best Buy

$56.72

0.66 (1.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 18

    Mar

TRP

TransCanada

$49.68

-0.58 (-1.15%)

14:33
11/22/17
11/22
14:33
11/22/17
14:33
Conference/Events
TransCanada to hold investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CERN

Cerner

$66.68

0.95 (1.45%)

, AMZN

Amazon.com

$1,139.49

13.18 (1.17%)

14:26
11/22/17
11/22
14:26
11/22/17
14:26
Recommendations
Cerner, Amazon.com analyst commentary  »

Cerner/AWS partnership…

CERN

Cerner

$66.68

0.95 (1.45%)

AMZN

Amazon.com

$1,139.49

13.18 (1.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 18

    Mar

14:25
11/22/17
11/22
14:25
11/22/17
14:25
General news
FOMC minutes showed concerns over low inflation »

FOMC minutes showed…

OTEX

OpenText

$33.91

0.38 (1.13%)

14:23
11/22/17
11/22
14:23
11/22/17
14:23
Hot Stocks
Battleground: Macquarie says sell OpenText, Raymond James remains bullish »

This morning, Macquarie…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FEIM

Frequency Electronics

$9.32

-0.11 (-1.17%)

14:22
11/22/17
11/22
14:22
11/22/17
14:22
Hot Stocks
Frequency Electronics appoints largest shareholder to its board »

Frequency Electronics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:20
11/22/17
11/22
14:20
11/22/17
14:20
General news
Treasury Action: yields remained at low ebb »

Treasury Action: yields…

$NSD

NASDAQ Market Internals

14:17
11/22/17
11/22
14:17
11/22/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
11/22/17
11/22
14:16
11/22/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SASR

Sandy Spring Bancorp

$38.98

0.04 (0.10%)

, WFBI

WashingtonFirst

$33.70

-0.13 (-0.38%)

14:12
11/22/17
11/22
14:12
11/22/17
14:12
Hot Stocks
Sandy Spring Bancorp reports receipt of all regulatory approvals for acquisition »

Sandy Spring Bancorp…

SASR

Sandy Spring Bancorp

$38.98

0.04 (0.10%)

WFBI

WashingtonFirst

$33.70

-0.13 (-0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

ILG

ILG

$28.11

-0.5 (-1.75%)

14:10
11/22/17
11/22
14:10
11/22/17
14:10
Options
Repeat option activity in ILG »

Repeat option activity in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

  • 30

    Nov

  • 01

    Dec

14:06
11/22/17
11/22
14:06
11/22/17
14:06
General news
Fed staff still see 'moderate' vulnerabilities in U.S. financial system »

The minutes from the…

14:02
11/22/17
11/22
14:02
11/22/17
14:02
General news
Fed minutes show 'many' saw 'near term' rate hike as warranted »

The minutes from the…

JACK

Jack in the Box

$102.57

-0.41 (-0.40%)

, APO

Apollo Global

$30.53

0.37 (1.23%)

13:59
11/22/17
11/22
13:59
11/22/17
13:59
Periodicals
Apollo near deal to buy Qdoba for over $300M, Reuters says »

Private equity firm…

JACK

Jack in the Box

$102.57

-0.41 (-0.40%)

APO

Apollo Global

$30.53

0.37 (1.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

SASR

Sandy Spring Bancorp

$38.98

0.04 (0.10%)

, WFBI

WashingtonFirst

$33.70

-0.13 (-0.38%)

13:52
11/22/17
11/22
13:52
11/22/17
13:52
Hot Stocks
Federal Reserve Board approves merger of Sandy Spring Bancorp, WashingtonFirst »

The Federal Reserve Board…

SASR

Sandy Spring Bancorp

$38.98

0.04 (0.10%)

WFBI

WashingtonFirst

$33.70

-0.13 (-0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

WEN

Wendy's

$14.11

0.16 (1.15%)

13:50
11/22/17
11/22
13:50
11/22/17
13:50
Options
Renewed interest in Wendy's 14-strike calls »

Renewed interest in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.